MedTrace Logo

Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)

NCT02051049 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2019-05-28

No results posted yet for this study

Summary

The purpose of this study is to assess the long-term safety follow-up of patients having been treated with HepaStem.

Conditions

  • Urea Cycle Disorders
  • Crigler Najjar Syndrome

Sponsors & Collaborators

  • Cellaion SA

    lead INDUSTRY

Principal Investigators

  • Françoise Smets, MD · Cliniques universitaires Saint-Luc (Belgium)

  • Dries Dobbelaere, MD/Prof · CHRU de Lille - Hopital Jeanne de Flandre (France)

  • Isabel Gonçalves, MD/Prof · Hospital Pediátrico de Coimbra (Portugal)

  • Stephanie Grunewald, MD · Great Ormond Street Children Hospital

  • Giuliano Torre, MD · IRCCS OSPEDALE PEDIATRICO DEL BAMBINO GESÃ (Roma)

  • Hanna Mandel, MD · Rambam Health Corporation

Eligibility

Max Age
23 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2018-04-30
Completion
2019-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02051049 on ClinicalTrials.gov